Tafasitamab and Lenalidomide reach the main end of the trial in Phase 2 clinical trials treating Patients with DLBCL

DLBCL is the most common non-Hodgkin's lymphoma (NHL) type, accounting for 40% of B-cell NHLIt is a rapidly moving NHL type30-40% of patients did not respond to the initial therapy or relapsedrecently, MorphoSyscompany(http://announced that the company's development of tafasitamab and lenalidomide, in the treatment of recurrent/incurable diffuse large B cell lymphoma (DLBCL) patients in the stage 2 clinicaltrial(http://About TafasitamabTafasitamab is an fc end optimized anti-CD19 monoclonal antibodyTafasitamab is a humanized monoclonal antibody that targets CD19 antigensCD19 is a widely expressed antigen in B cell cancer, which enhances the signaling pathway sway of B-cell receptor-mediated, supporting B-cell survivalIt is an important target for B-cell cancerMorphoSys optimized the Fc end of tafasitamab to enhance its ability to trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP)In preclinical models, tafasitamab can directly lead to apoptosis by binding to CD19The U.S FDA (http:// has granted this therapy breakthrough therapy for use in patients with recurrent/incurable DLBCL In this Phase 2 clinical trial called L-MIND, 80 patients with recurrent/refractory DLBCL were treated with a combination of tafasitamab and lenalidomide These patients are not suitable for intensive chemotherapy or stem cell transplant therapy results showed that patients treated reached an objective remission rate (ORR) of 60% and a full remission rate (CR) of 43% At a median follow-up period of 17.3 months, the median progression-free life span (PFS) in patients was 12.1 months